Key result
Aspirin dosing (325 mg/day vs 81 mg/day) did not affect pharmacodynamic measures of ADP-mediated platelet reactivity irrespective of the degree of P2Y12 receptor blockade.
Why the study?
Does aspirin dose (325 mg vs 81 mg) affect ADP-mediated platelet reactivity in patients with stable coronary artery disease treated with prasugrel's active metabolite?
Does aspirin dose (325 mg vs 81 mg) affect ADP-mediated platelet reactivity in patients with stable coronary artery disease treated with prasugrel's active metabolite?
p-value: p=0.899
Aspirin dosing (81 mg vs 325 mg) does not affect pharmacodynamic measures of ADP-mediated platelet reactivity, regardless of the degree of P2Y12 receptor blockade.
No takes yet. Share an insight, caveat, or question.
No aspirin dose effect on ADP reactivity supports no PD-based adjustment; leaves open clinical outcome implications in stable CAD.
Tello‐Montoliu et al. (2013) studied stable coronary artery disease (n=26). Aspirin vs. Aspirin 81 mg/day was evaluated on ADP-mediated platelet reactivity (VASP-PRI) (p=p=0.899). Aspirin dosing (325 mg/day vs 81 mg/day) did not affect pharmacodynamic measures of ADP-mediated platelet reactivity irrespective of the degree of P2Y12 receptor blockade.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: